Synairgen (LON:SNG) Trading Up 22% – Here’s Why

Shares of Synairgen plc (LON:SNG) rose 22% during mid-day trading on Wednesday . The stock traded as high as GBX 2.71 ($0.03) and last traded at GBX 2.68 ($0.03). Approximately 1,771,337 shares were traded during trading, an increase of 25% from the average daily volume of 1,421,729 shares. The stock had previously closed at GBX 2.20 ($0.03).

Synairgen Stock Performance

The firm has a market cap of £5.48 million, a PE ratio of -90.67 and a beta of -2.23. The stock has a 50-day moving average price of GBX 3.69 and a 200 day moving average price of GBX 3.99. The company has a debt-to-equity ratio of 0.09, a current ratio of 6.77 and a quick ratio of 6.35.

Synairgen Company Profile

Synairgen is a respiratory drug discovery and development company founded by University of Southampton Professors Stephen Holgate, Donna Davies and Ratko Djukanovic. The business, focused primarily on lung viral defence in asthma and COPD, uses its differentiating human biology BioBank platform and world-renowned international academic KOL network to discover and develop novel therapies for respiratory disease.

Synairgen is conducting a double blind, placebo-controlled clinical trial in COVID-19 patients (SG016).